Both in Pharmaceuticals
Protagonist Therapeutics vs Cytokinetics
Over the past year PTGX returned +116.4% and CYTK returned +21.8%; their daily moves had a correlation of 0.25.
PTGX +116.4% CYTK +21.8%Growth of $1, one year, split-adjusted
| Metric | PTGX | CYTK |
|---|---|---|
| Price | $140.97 | $65.64 |
| Market cap | $9.12B | $9.13B |
| Today | −1.03% | −0.79% |
| 1 month | −2.3% | −8.9% |
| 6 months | +41.2% | +4.2% |
| Year to date | +61.4% | +3.3% |
| 1 year | +109.1% | +30.2% |
| Revenue growth (YoY) | +3749.2% | −57.1% |
| Gross margin | 100.0% | 90.5% |
| Net margin | 76.3% | −694.4% |
| P/E (TTM) | 110.0× | — |
| Price / sales | 32.3× | 134.9× |
| Net cash | $782.6M | $18.6M |
| Dividend yield | — | — |
| Volatility (60d) | 40.1% | 33.7% |
| Short % of float | 13.9% | 14.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).